keyword
MENU ▼
Read by QxMD icon Read
search

Muscle invasive bladder cancer

keyword
https://www.readbyqxmd.com/read/28540249/liquid-biopsies-for-bladder-cancer
#1
EDITORIAL
Douglas G Ward, Richard T Bryan
The development of accurate urinary biomarkers for the non-invasive detection of urothelial bladder cancer (UBC) could transform patient pathways by reducing reliance on cystoscopy, and the identification of highly prognostic (or even predictive) biomarkers could better guide patient management. A number of approaches are being utilised to address these challenges in both urinary- and plasma-borne tumour DNA (tDNA), so-called "liquid biopsies". Next generation sequencing (NGS) and droplet digital PCR (ddPCR) allow detection of very low levels of such tDNA amongst a large excess of non-tumour DNA, the former permitting large mutation panels to be assessed and the latter potentially identifying ultrarare mutant alleles yet restricted for multiplexing...
April 2017: Translational Andrology and Urology
https://www.readbyqxmd.com/read/28537702/the-awareness-of-patients-with-non-muscle-invasive-bladder-cancer-regarding-the-importance-of-smoking-cessation-and-their-access-to-smoking-cessation-programs
#2
Emrah Yuruk, Murat Tuken, Aykut Colakerol, Ege Can Serefoglu
OBJECTIVES: Smoking is the most important risk factor for bladder cancer and smoking cessation is associated with reduced risk of tumor recurrence and progression. The aim of this study is to assess the awareness of non-muscle invasive bladder cancer (NMIBC) patients regarding the importance of smoking cessation, determine their access to smoking cessation programs and the effects of smoking cessation on recurrence rates of NMIBC. MATERIALS AND METHODS: NMIBC patients who were followed with cystoscopy were included in the study...
May 23, 2017: International Braz J Urol: Official Journal of the Brazilian Society of Urology
https://www.readbyqxmd.com/read/28535714/non-muscle-invasive-bladder-cancer-a-vision-for-the-future
#3
Per-Uno Malmström, Sachin Agrawal, Mats Bläckberg, Peter J Boström, Bernard Malavaud, Dirk Zaak, Gregers G Hermann
The management of non-muscle-invasive bladder cancer (NMIBC) has evolved from the first reports on bladder endoscopy and transurethral resection to the introduction of adjuvant intravesical treatment. However, disease recurrence and progression remain an ongoing risk, placing a heavy burden on healthcare resources and on patients' quality of life. Deeper understanding of the molecular basis of the disease and developments in optics, lasers and computer science are already offering opportunities to revolutionize care and improve long-term prognosis...
February 7, 2017: Scandinavian Journal of Urology
https://www.readbyqxmd.com/read/28533583/high-grade-urothelial-carcinoma-of-bladder-transforming-to-micropapillary-variant-on-follow-up
#4
Nitu Kumari, Anupama Jha, Pawan Vasudeva, Usha Agrawal
Micropapillary variant of urothelial carcinoma (UC) of the bladder is an aggressive tumour, comprising 0.6-6% of all UC. It generally presents with high-grade and stage, and has been reported as having a worse prognosis when compared to traditional UC. We report the case of a 58-year-old man who presented with macroscopic haematuria. The patient was diagnosed with high-grade urothelial carcinoma and returned with recurrence after 16 months. Histopathology after transurethral biopsy revealed a non-muscle invasive high-grade bladder tumour at first presentation, whereas tumour recurrence was reported after 1...
May 2017: Iranian Journal of Medical Sciences
https://www.readbyqxmd.com/read/28529600/prospective-evaluation-of-fluorescence-in-situ-hybridization-for-diagnosing-urothelial-carcinoma
#5
Tianhai Lin, Zhenhua Liu, Liangren Liu, Lu Yang, Ping Han, Peng Zhang, Qiang Wei
Urothelial carcinoma (UC) is the most common type of cancer of the bladder and upper urinary tract, and is characterized by a high risk of recurrence and progression. Urine fluorescence in situ hybridization (FISH) is a technique that detects genetic aberrations in exfoliated cells in the urine, with specific probes for chromosomes 3, 7 and 17 and the p16 gene. To evaluate the diagnostic value of FISH in UC, 119 patients from November 2010 to June 2012 with suspected UC were recruited into a prospective, cross-sectional study and were followed up for 12-30 months...
May 2017: Oncology Letters
https://www.readbyqxmd.com/read/28516158/a-management-algorithm-for-mitomycin-c-induced-cystitis
#6
Amy N Luckenbaugh, Rory M Marks, David C Miller, Alon Z Weizer, John T Stoffel, Jeffrey S Montgomery
Background/Objective: A post-bladder tumor resection dose of MMC can reduce non-invasive papillary (pTa) bladder cancer recurrences by up to 40%; this treatment is recommended in both the AUA and EUA non-muscle-invasive bladder cancer guidelines. A common complication of this treatment is eosinophilic cystitis. Symptoms range from mild urinary frequency and urgency to debilitating pain and dysuria. Currently, there is no established treatment algorithm for MMC-induced cystitis. Methods: Members of the Urologic Surgery Quality Collaborative (USQC), a group composed of over 160 private and academic urologists, met to discuss the management of patients with cystitis following MMC therapy...
April 27, 2017: Bladder Cancer
https://www.readbyqxmd.com/read/28516155/phase-i-clinical-trial-of-everolimus-combined-with-trimodality-therapy-in-patients-with-muscle-invasive-bladder-cancer
#7
Bassel G Bachir, Luis Souhami, Jose João Mansure, Fabio Cury, Marie Vanhuyse, Fadi Brimo, Armen G Aprikian, Simon Tanguay, Jeremy Sturgeon, Wassim Kassouf
Background: Local control following trimodality therapy (TMT) for muscle-invasive bladder cancer (MIBC) requires further optimization. Objective: Evaluating the biologic endpoint, feasibility, and toxicity of integrating everolimus to TMT in patients with MIBC. Methods: This was a phase I trial in patients with MIBC who were not surgical candidates or who refused cystectomy. Following maximal transurethral tumor resection, patients were treated by radiotherapy (50 Gy/20 fractions), gemcitabine (100 mg/m2/weekly) and escalating doses of everolimus (2...
April 27, 2017: Bladder Cancer
https://www.readbyqxmd.com/read/28516152/cdk4-6-inhibitors-in-cancer-therapy-a%C3%A2-novel-treatement-strategy-for-bladder-cancer
#8
REVIEW
Qi Pan, Anuja Sathe, Peter C Black, Peter J Goebell, Ashish M Kamat, Bernd Schmitz-Draeger, Roman Nawroth
Patients with metastatic bladder cancer (mBC) treated with cisplatin-based chemotherapy have a limited median survival of only around 14 months [1]. Despite over 30 years of basic and clinical research, until recently no therapeutic options beyond cisplatin-based therapy had entered clinical routine and, at least in the US, none of the tested agents had been approved for second-line treatment. This has changed with the advent of immune checkpoint blockade, including especially PD-1/PD-L1 inhibitors. The high response rates of 24% over a 14...
April 27, 2017: Bladder Cancer
https://www.readbyqxmd.com/read/28507799/characterization-of-a-human-anti-tumoral-nk-cell-population-expanded-after-bcg-treatment-of-leukocytes
#9
Eva M García-Cuesta, Gloria Esteso, Omodele Ashiru, Sheila López-Cobo, Mario Álvarez-Maestro, Ana Linares, Mei M Ho, Luis Martínez-Piñeiro, Hugh T Reyburn, Mar Valés-Gómez
Immunotherapy, via intra-vesical instillations of BCG, is the therapy of choice for patients with high-risk non-muscle invasive bladder cancer. The subsequent recruitment of lymphocytes and myeloid cells, as well as the release of cytokines and chemokines, is believed to induce a local immune response that eliminates these tumors, but the detailed mechanisms of action of this therapy are not well understood. Here, we have studied the phenotype and function of the responding lymphocyte populations as well as the spectrum of cytokines and chemokines produced in an in vitro model of human peripheral blood mononuclear cells (PBMCs) co-cultured with BCG...
2017: Oncoimmunology
https://www.readbyqxmd.com/read/28507798/tumor-infiltrating-neutrophils-predict-benefit-from-adjuvant-chemotherapy-in-patients-with-muscle-invasive-bladder-cancer
#10
Lin Zhou, Le Xu, Lingli Chen, Qiang Fu, Zheng Liu, Yuan Chang, Zongming Lin, Jiejie Xu
Growing evidence shows tumor-infiltrating neutrophils (TINs) involvement in tumorigenesis. The objective of this study is to assess the prognostic effect of TINs and its impact on adjuvant chemotherapy benefits in muscle invasive bladder cancer (MIBC). A total of 142 MIBC patients from Zhongshan Hospital, 119 MIBC patients from FUSCC, and 405 MIBC patients from TCGA cohort were enrolled in the study. TINs were evaluated by immunohistochemical staining of CD66b or the CIBERSORT method. Patients with high TINs had a significantly poorer overall survival (p = 0...
2017: Oncoimmunology
https://www.readbyqxmd.com/read/28505892/re-oncologic-outcomes-of-kidney-sparing-surgery-versus-radical-nephroureterectomy-for-upper-tract-urothelial-carcinoma-a-systematic-review-by-the-eau-non-muscle-invasive-bladder-cancer-guidelines-panel
#11
https://www.readbyqxmd.com/read/28504717/fibulin-3-promotes-muscle-invasive-bladder-cancer
#12
A L Han, B A Veeneman, L El-Sawy, K C Day, M L Day, S A Tomlins, E T Keller
Urothelial carcinoma is the most common type of bladder cancer and can be categorized as either non-muscle-invasive (Ta-T1) or muscle-invasive (⩾T2). The majority of bladder cancers are non-muscle-invasive at presentation; however, the recurrence rate for these tumors is high and a subset can progress to T2. In this study, we aimed to identify genes differentially expressed between T1 vs T2 bladder cancer to identify key regulators of bladder cancer progression and/or invasion. We performed RNA-Seq on T1 and T2 bladder cancer tissues and used publicly available bladder cancer profiling studies to prioritize differentially expressed genes for validation and functional assessment...
May 15, 2017: Oncogene
https://www.readbyqxmd.com/read/28498805/foxm1-predicts-overall-and-disease-specific-survival-in-muscle-invasive-urothelial-carcinoma-and-presents-a-differential-expression-between-bladder-cancer-subtypes
#13
Sebastien Rinaldetti, Ralph Markus Wirtz, Thomas Stefan Worst, Markus Eckstein, Cleo Aaron Weiss, Johannes Breyer, Wolfgang Otto, Christian Bolenz, Arndt Hartmann, Philipp Erben
Forkhead box M1 (FOXM1) is a late cell cycle gene that plays a crucial role in carcinogenesis and chemotherapeutic drug resistance. In this study, the impact of FOXM1 expression on patient outcome was investigated for the first time in formalin fixed and paraffin embedded (FFPE) samples of chemotherapy naïve muscle-invasive bladder cancer (MIBC) patients. Expression analyses were performed on the Mannheim cohort (n=84) and validated on the independent Chungbuk cohort (n=61). In a Cox' proportional hazards model, a distinct FOXM1 expression cut-off dividing both cohorts in a 'high-risk' and 'low-risk' group has been determined...
April 24, 2017: Oncotarget
https://www.readbyqxmd.com/read/28494780/metastatic-non-muscle-invasive-bladder-cancer-with-meningeal-carcinomatosis-case-report-of-an-unexpected-response
#14
Diego Teyssonneau, Amaury Daste, Vincent Dousset, Jean-Luc Hoepffner, Alain Ravaud, Marine Gross-Goupil
BACKGROUND: Non-muscle invasive bladder cancer (NMIBC) is usually treated with local therapy including transurethral resection of the bladder tumor and intravesical therapy depending on the stage of the tumor. NMIBC is a rarely a metastatic diseases with lymph node invasion in less of 10%. In the other hand meningeal carcinomatosis is a rare location for metastases with extremely poor outcomes. We described a case report of a patient presenting a metastatic disease to bones and meninges, several years after the treatment of NMIBC, which had been in complete response (CR) for 4 years after chemotherapy treatment...
May 11, 2017: BMC Cancer
https://www.readbyqxmd.com/read/28493171/immunotherapy-in-urothelial-cancer-recent-results-and-future-perspectives
#15
REVIEW
Matthew S Farina, Kevin T Lundgren, Joaquim Bellmunt
Cytotoxic chemotherapy has been the only systemic treatment of locally advanced and metastatic urothelial carcinoma for decades. Long-term survival remains stagnant around 12-14 months for patients with advanced disease who have progressed on or recurred after receiving first-line platinum-based chemotherapy. Improving clinical outcomes for patients with urothelial carcinoma in all disease settings requires the development of novel treatments, especially for patients who failed on first-line chemotherapy. Since the discovery of intravesical Bacillus-Calmette Guerin (BCG) in the 1970s for non-muscle invasive disease, there have not been any major breakthrough drugs that exploit the immune-sensitivity of bladder cancer until recently...
May 11, 2017: Drugs
https://www.readbyqxmd.com/read/28489981/evolving-treatment-of-advanced-urothelial-cancer
#16
Srikala S Sridhar
Urothelial cancer of the bladder is a smoking-related cancer and the fifth most common cancer in the United States. At presentation, up to 25% of patients will have muscle-invasive disease and, despite cystectomy or bladder-sparing trimodality approaches, will develop metastatic disease. Cisplatin-based combination chemotherapy regimens remain the standard of care in first-line metastatic disease. Although response rates to these regimens are high, they are rarely durable, and median overall survival is only 12 to 15 months...
May 2017: Journal of Oncology Practice
https://www.readbyqxmd.com/read/28488575/proteomics-analysis-of-bladder-cancer-invasion-targeting-eif3d-for-therapeutic-intervention
#17
Agnieszka Latosinska, Marika Mokou, Manousos Makridakis, William Mullen, Jerome Zoidakis, Vasiliki Lygirou, Maria Frantzi, Ioannis Katafigiotis, Konstantinos Stravodimos, Marie C Hupe, Maciej Dobrzynski, Walter Kolch, Axel S Merseburger, Harald Mischak, Maria G Roubelakis, Antonia Vlahou
Patients with advanced bladder cancer have poor outcomes, indicating a need for more efficient therapeutic approaches. This study characterizes proteomic changes underlying bladder cancer invasion aiming for the better understanding of disease pathophysiology and identification of drug targets. High resolution liquid chromatography coupled to tandem mass spectrometry analysis of tissue specimens from patients with non-muscle invasive (NMIBC, stage pTa) and muscle invasive bladder cancer (MIBC, stages pT2+) was conducted...
April 20, 2017: Oncotarget
https://www.readbyqxmd.com/read/28487492/sequencing-of-cancer-cell-subpopulations-identifies-micrometastases-in-a-bladder-cancer-patient
#18
Kris Prado, Kelvin X Zhang, Matteo Pellegrini, Arnold I Chin
PURPOSE: Pathologic staging of bladder cancer patients remains a challenge. Standard-of-care histology exhibits limited sensitivity in detection of micrometastases, which can increase risk of cancer progression and delay potential adjuvant therapies. Here, we sought to develop a proof of concept novel molecular approach to improve detection of cancer micrometastasis. EXPERIMENTAL DESIGN: We combined fluorescence activated cell sorting and next-generation sequencing and performed whole-exome sequencing of total cancer cells and cancer cell subpopulations in multiple tumor specimens and regional lymph nodes in a single patient with muscle-invasive urothelial carcinoma of the bladder following radical cystectomy...
April 21, 2017: Oncotarget
https://www.readbyqxmd.com/read/28487100/differential-expression-of-pd-l1-in-high-grade-t1-vs-muscle-invasive-bladder-carcinoma-and-its-prognostic-implications
#19
Stephanie A M Wankowicz, Lillian Werner, Anna Orsola, Jesse Novak, Michaela Bowden, Toni K Choueiri, Inés de Torres, Juan Morote, Gordon J Freeman, Sabina Signoretti, Joaquim Bellmunt
PURPOSE: PD-1 ligand (PD-L1) is expressed on both tumor cells (TCs) and tumor immune cell infiltrates (TIMC). In metastatic bladder cancer, increased TIMC PD-L1 positivity (PD-L1+) was correlated with better overall survival, however, in high grade T1 bladder tumors (HGT1) PD-L1+ on TCs and TIMCs, and correlation with outcome or pathological features remain unknown. MATERIALS AND METHODS: Formalin-fixed paraffin embedded (FFPE) tumor samples from 140 clinically annotated HGT1patients (pts) were retrieved...
May 6, 2017: Journal of Urology
https://www.readbyqxmd.com/read/28483329/trimodal-therapy-is-inferior-to-radical-cystectomy-for-muscle-invasive-bladder-cancer-using-population-level-data-is-there-evidence-in-the-lack-of-details
#20
EDITORIAL
Girish S Kulkarni, Zachary Klaassen
No abstract text is available yet for this article.
May 5, 2017: European Urology
keyword
keyword
21307
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"